Search details
1.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
Cell
; 175(7): 1731-1743.e13, 2018 12 13.
Article
in English
| MEDLINE | ID: mdl-30503213
2.
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 73(4): 70, 2024 Mar 02.
Article
in English
| MEDLINE | ID: mdl-38430375
3.
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
BMC Cancer
; 23(1): 663, 2023 Jul 14.
Article
in English
| MEDLINE | ID: mdl-37452287
4.
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Oncologist
; 27(2): e194-e198, 2022 03 04.
Article
in English
| MEDLINE | ID: mdl-35641218
5.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 22(4): 463-475, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33684370
6.
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Invest New Drugs
; 38(6): 1774-1783, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32410080
7.
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Cancer
; 125(18): 3208-3218, 2019 09 15.
Article
in English
| MEDLINE | ID: mdl-31246283
8.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
N Engl J Med
; 375(19): 1856-1867, 2016 11 10.
Article
in English
| MEDLINE | ID: mdl-27718784
9.
Systematic screening for occupations and occupational exposures in head and neck squamous cell carcinoma patients.
Eur Arch Otorhinolaryngol
; 276(3): 857-864, 2019 Mar.
Article
in English
| MEDLINE | ID: mdl-30607561
10.
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Oncologist
; 23(9): 1079-1082, 2018 09.
Article
in English
| MEDLINE | ID: mdl-29866947
11.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Article
in English
| MEDLINE | ID: mdl-26412456
12.
Nivolumab in recurrent/metastatic head and neck cancers.
Future Oncol
; 14(7): 603-609, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-29130342
13.
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Lancet Oncol
; 18(8): 1104-1115, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28651929
14.
Chemotherapy for localized head and neck squamous cell cancers.
Anticancer Drugs
; 28(4): 362-368, 2017 04.
Article
in English
| MEDLINE | ID: mdl-28134662
15.
Chemotherapy for recurrent/metastatic head and neck cancers.
Anticancer Drugs
; 28(4): 357-361, 2017 04.
Article
in English
| MEDLINE | ID: mdl-28166090
16.
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Lancet Oncol
; 16(5): 583-94, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25892145
17.
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
BMC Cancer
; 14: 504, 2014 Jul 10.
Article
in English
| MEDLINE | ID: mdl-25011678
18.
A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.
Anticancer Drugs
; 25(8): 970-5, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-24849707
19.
[Oncology in French Guiana: A challenge to win]. / La cancérologie en Guyane : un défi à gagner.
Bull Cancer
; 2024 May 14.
Article
in French
| MEDLINE | ID: mdl-38749776
20.
Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.
Oral Oncol
; 149: 106680, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38218022